1. Home
  2. MARPS vs OGEN Comparison

MARPS vs OGEN Comparison

Compare MARPS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marine Petroleum Trust Units of Beneficial Interest

MARPS

Marine Petroleum Trust Units of Beneficial Interest

HOLD

Current Price

$4.99

Market Cap

9.9M

Sector

Energy

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.59

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARPS
OGEN
Founded
1956
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
2.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MARPS
OGEN
Price
$4.99
$0.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.2K
47.5K
Earning Date
02-13-2026
05-11-2026
Dividend Yield
6.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.70
$0.11
52 Week High
$6.49
$9.16

Technical Indicators

Market Signals
Indicator
MARPS
OGEN
Relative Strength Index (RSI) 50.60 43.53
Support Level $4.17 N/A
Resistance Level $5.20 $0.66
Average True Range (ATR) 0.14 0.04
MACD 0.01 -0.00
Stochastic Oscillator 48.01 32.34

Price Performance

Historical Comparison
MARPS
OGEN

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: